Moderna, Inc. (NASDAQ:MRNA) Receives $90.22 Average Price Target from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been assigned a consensus rating of “Hold” from the twenty-two analysts that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $84.00.

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Sanford C. Bernstein assumed coverage on shares of Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 target price on the stock. JPMorgan Chase & Co. cut their target price on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research note on Monday, November 4th. TD Cowen lowered their price objective on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Finally, HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Monday, November 18th.

Moderna Trading Up 7.5 %

Shares of MRNA stock opened at $41.11 on Monday. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $54.96 and its two-hundred day moving average price is $93.90.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.39) EPS. On average, research analysts anticipate that Moderna will post -9.44 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders sold 2,930 shares of company stock valued at $217,170. Company insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Moderna

Several hedge funds have recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the 2nd quarter valued at approximately $26,000. Family Firm Inc. acquired a new position in Moderna in the 2nd quarter valued at approximately $33,000. Bank & Trust Co acquired a new position in Moderna in the 2nd quarter valued at approximately $36,000. Hanseatic Management Services Inc. acquired a new position in Moderna in the 2nd quarter valued at approximately $48,000. Finally, Plato Investment Management Ltd increased its stake in Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after buying an additional 288 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.